SCHEMBL22200826

SCHEMBL22200826

Cc1ccc(CSNc2c(F)cc(-c3nc4cnc(N)nc4n(C(C)C)c3=O)cc2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.39
MTOR P42345 5/20 0.37
USP2 O75604 7/20 0.35
CYP1A2 P05177 6/20 0.35
CASP1 P29466 4/20 0.35
HIF1A Q16665 4/20 0.35
CASP7 P55210 3/20 0.35
TSHR P16473 3/20 0.35
CYP3A4 P08684 4/20 0.34
CYP2C9 P11712 3/20 0.34
RPS6KA3 P51812 1/20 0.33
ALDH1A1 P00352 4/20 0.33
HSD17B10 Q99714 3/20 0.33
PIK3CA P42336 3/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
KMT2A Q03164 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
MAPK1 P28482 2/20 0.33
CYP2C19 P33261 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200788 0.94 USP2 (0.40) ERN1USP2CYP1A2CASP1HIF1A
SCHEMBL22200635 0.92 ERN1 (0.39) ERN1USP2CYP1A2CASP1HIF1A
SCHEMBL22200816 0.92 ERN1 (0.38) ERN1MTORUSP2CYP1A2CASP1
SCHEMBL22200799 0.89 RORC (0.34) ERN1MTORRPS6KA3PIK3CARORC
SCHEMBL22200549 0.89 ERN1 (0.37) ERN1MTORUSP2CYP1A2CASP1
SCHEMBL25035365 0.84 ERN1 (0.47) ERN1MTORUSP2CYP1A2CASP1
SCHEMBL22200603 0.84 ERN1 (0.43) ERN1MTORUSP2CYP1A2CASP1
SCHEMBL22200594 0.83 RORC (0.34) ERN1USP2CYP1A2CASP1HIF1A
SCHEMBL22200719 0.83 ERN1 (0.42) ERN1MTORUSP2CYP1A2CASP1
SCHEMBL22200786 0.82 ERN1 (0.43) ERN1MTORUSP2CYP1A2CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed